​B​ioSig Technologies Announces Advanced Research Program with Mayo Clinic

BioSig Technologies (OTCQB:BSGM) announced the establishment of an advanced research program with Dr. Samuel Asirvatham at the Mayo Clinic in Rochester, Minnesota. This program has been designed to build upon the initial studies conducted at Mayo Clinic in March, June and November 2015 through a tripling of investment to fully characterize and develop novel features discovered during this prior preclinical work.  These features have the potential to make significant impact in the treatment of complex arrhythmias.
BioSig Technologies President and CEO, Greg Cash, stated:

We are extremely pleased to continue our relationship with Dr. Asirvatham and his colleagues at the Mayo Clinic. The previous studies confirmed the potential of PURE EP to improve the clarity of cardiac signals while minimizing electrical noise in the cardiac electrophysiology laboratory.

Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.